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Combined modality treatment (CMT) is the preferred treatment for anal squamous cell 
carcinoma, but a small subgroup needs a defunctioning colostomy with temporary intent. 
 
Aim 
The aim of this study was to evaluate the stoma closure rate of patients needing de-
functioning colostomies prior to CMT for anal squamous cell carcinoma (SCC) at Groote 
Schuur Hospital (GSH). The key objective was to assess if abdomino-perineal resection 
(APR) should be offered as primary treatment modality for the subgroup of patients needing 
a defunctioning stoma and CMT.  
 
Method 
A retrospective chart review of all patients with histological diagnoses of anal squamous 
carcinoma treated at the Combined Colorectal Clinic at Groote Schuur Hospital between 
1995 and 2012 were undertaken.  Patients who required defunctioning colostomies prior to 
CMT were analysed in terms of demographics, indication for stoma, response to treatment 
and stoma closure rate. 
 
Results 
125 patients were treated for anal SCC.  There were 58 males and 67 females with a 
median age of 56 years.  Thirty nine patients were deemed to require a defunctioning stoma 
prior to CMT.  Thirty of these patients were treated with curative intent (22 males and 8 
females) and a defunctioning stoma.   The indications for stomas were obstruction (n=14); 
incontinence (n=8); pain (n=4); fistula (n=3) and sepsis (n=1). In only three (10%) of the 30 
patients were the stomas successfully reversed.    Disease progression (n=15) was the 
leading reason for non-reversal of defunctioning stomas.  Thirteen of the 30 patients who 
needed a stoma prior to CMT were clearly not resectable, while 6 were evaluated on the pre-




In this study we found that a defunctioning stoma prior to CMT was likely to be permanent.  






Should abdomino-perineal resection be considered when a defunctioning stoma is 
required for anal canal squamous cell carcinoma?   
Dr JC Kloppers Supervisor:  Prof PA Goldberg 
1. Introduction and background:
Squamous cell carcinoma (SCC) of the anal canal is rare.  In the United States, for the year 
2012, 780 deaths due to SCC were expected with 6230 new diagnoses.1 The condition 
comprises 4% of the total number of cancers of the gastrointestinal tract seen at Groote 
Schuur Hospital (GSH).2   Ninety percent of anal canal carcinomas are of squamous cell 
origin. The remainder consists of rarer subtypes including adenocarcinoma, melanoma, and 
neuroendocrine carcinoma of the anal canal.3 This study will include patients with squamous 
cell carcinoma of both the anal canal and anal margin. 
Abdomino-perineal resection (APR) was the standard of care for anal canal squamous cell 
carcinoma before the introduction of combined modality therapy (CMT).4,5  In 1974 Nigro et 
al introduced CMT as primary therapy for SCC.6  In their series a complete pathological 
response rate of 93% was seen in over 100 patients treated by CMT.  Currently, CMT is the 
recommended first line therapy for invasive SCC of the anal canal.  Surgical resection is now 
reserved as salvage therapy for patients with persistent disease, recurrent disease or for the 
treatment of complications associated with radiation therapy.7 The current treatment protocol 
at GSH combined colorectal clinic correlates with the above.8 
Some patients require a defunctioning colostomy prior to CMT to allow for safe delivery of 
treatment with the lowest risk of treatment interruption.  The indications include the presence 
or risk of fistula formation, symptoms of large bowel obstruction or faecal incontinence; the 
latter is usually due to destruction of the anal sphincter by tumour.8-11 In a recent review at 
GSH, seven (23%) out of 31 patients over a four year period required a stoma prior to CMT; 
of these only one was closed.2   In Leeds, 35 (10%) out of 344 patients over a ten year 
period required stomas prior to CMT of which seven were closed.9  These findings were 
similar to those found in a Dutch study of 83 patients with anal cancer. In their series, seven 
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patients (8%) had a colostomy created before treatment with only one being permanently 
reversed.12 
The major benefit of CMT is preservation of the anus and thus avoiding a permanent stoma.  
The literature would suggest that pre-treatment colostomy in anal carcinoma should be 
regarded as permanent.9,10,12  If this is so, then APR would potentially shorten treatment and 
avoid the complications and frequent hospital visits of CMT.  Common complications of CMT 
include diarrhoea, haematological toxicity and skin disruption.  Although APR is regarded as 
major surgery it requires only one admission and limited follow up in most cases.  APR as 
primary treatment for patients with SCC of the anus, who require defunctioning, has not 
been previously evaluated. 
2. Methodology: 
This study involves a retrospective folder review of patients with SCC at GSH. 
Objective: 
1. To evaluate the stoma closure rate of patients who required defunctioning 
colostomies prior to CMT for Anal SCC at GSH. 
2. To assess whether APR is a suitable primary treatment modality for the subgroup of 
patients needing a defunctioning stoma prior to CMT. 
Inclusion criteria: 
All patients with histologically proven anal SCC treated at the Combined Colorectal Clinic, 
Groote Schuur Hospital, Cape Town from January 1998 to June 2012 will be reviewed.  
Recruitment of sample: 
1. Patients will be identified from an electronic database updated by the GSH Oncology 
Department. 
2. In addition there will be a manual search of appointment diaries of the Combined 
Colorectal Clinic since 1998. 
 
Data collection and storage: 
Data will be collected manually from patient folders and captured on a digital Microsoft Excel 
2010 spreadsheet.    
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Demographical information, TNM stage, potential resectability of the tumour prior to CMT, 
HIV status, co-morbidities, complications and length of CMT, type of stoma, indication for 
stoma, closure rate and evaluation at EUA will be collected 
Protection of confidentiality: 
All information obtained that can be identified to specific patients will remain confidential. 
Patient folders will only be viewed by health professionals who are legally and ethically 
bound to upholding confidentiality. Additionally, all data digitally captured for the purpose of 
this study will be password protected. Any reports or publications resulting from the research 
will maintain the anonymity of the individual study participants. 
3. Anticipated risks: 
No direct risk to patients is anticipated in this retrospective study. 
4. Anticipated benefits: 
The study will have no direct benefit to patients included within the study. However, it will 
consolidate local understanding regarding which patients require defunctioning colostomy as 
well as explore reasons for non-reversal of temporary stomas.  This may lead to improved 
informed consent and wider surgical options in first line treatment of anal carcinoma for 
future patients. 
5. Ethical considerations: 
As the data used is routine data and will be retrospectively and anonymously collected from 
files, no violation of privacy is expected.  Consent will be obtained from the medical 
superintendent of Groote Schuur Hospital for access to these files and hospital databases. A 
waiver of need for direct consent from patients is requested, as this is a retrospective file 
review.  No risks to the patients are anticipated and obtaining consent would be extremely 
difficult due to the retrospective nature of the study.  
6. Budget: 
Stationary costs (paper, printing) R150  
Electronic communication   R 50 
Password-protected flash drive R150 
Total     R350 
 Source of funding:  Principal investigator 
9 
 
       7.  References: 
(1) Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012                   
Jan-Feb;62(1):10-29.  
(2) Robertson B, Shepherd L, Abratt RP, Hunter A, Goldberg P. Treatment of carcinoma of the anal 
canal at Groote Schuur Hospital. S Afr Med J 2012 May 23;102(6):559-561.  
(3) Eng C. Carcinoma of the anal canal: small steps in treatment advances. Clin Adv Hematol Oncol 
2011 Sep;9(9):662-669.  
(4) Lopez MJ, Bliss DP,Jr, Kraybill WG, Soybel DI. Carcinoma of the anal region. Curr Probl Surg 
1989 Aug;26(8):525-600.  
(5) Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, et al. Squamous-cell 
carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008  
Feb;51(2):147-153.  
(6) Nigro ND, Vaitkevicius VK, Considine B,Jr. Combined therapy for cancer of the anal canal: a 
preliminary report. 1974. Dis Colon Rectum 1993 Jul;36(7):709-711.  
(7) Rousseau DL,Jr, Thomas CR,Jr, Petrelli NJ, Kahlenberg MS. Squamous cell carcinoma of the 
anal canal. Surg Oncol 2005 Nov;14(3):121-132.  
(8) Robertson B. Protocol for the management of carcinoma of the anal canal. Combined colorectal 
clinic - Groote Schuur Hospital 2009 September:1-8.  
(9) Cooper R, Mason M, Finan P, Byrne P, Sebag-Montefiore D. Defunctioning stomas prior to 
chemoradiation for anal cancer are usually permanent. Colorectal Dis 2012 Jan;14(1):87-91.  
(10) Sunesen KG, Norgaard M, Lundby L, Havsteen H, Buntzen S, Thorlacius-Ussing O, et al. Cause-
specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study. J Clin 
Oncol 2011 Sep 10;29(26):3535-3540.  
(11) Nguyen WD, Mitchell KM, Beck DE. Risk factors associated with requiring a stoma for the 
management of anal cancer. Dis Colon Rectum 2004 Jun;47(6):843-846.  
(12) de Bree E, van Ruth S, Dewit LG, Zoetmulder FA. High risk of colostomy with primary 












 Chapter 1 
Literature review 
Squamous cell carcinoma (SCC) of the anus is a relatively rare condition.  It comprises 4% 
of the total number of cancers of the gastrointestinal tract seen at Groote Schuur Hospital 
(GSH).1 Abdomino-perineal resection (APR) was the standard of care before it was replaced 
by combined modality therapy (CMT) which was introduced by Nigro et el in 1974.2 Some 
patients will require a defunctioning colostomy prior to CMT to allow for safe delivery of 
treatment with the lowest risk of treatment interruption. However the literature would suggest 
that a pre-treatment colostomy in anal carcinoma should be regarded as permanent.3-5 
1.1 Anatomy of the anus 
The anus can be divided into the anal canal and the anal margin.6 The anal canal starts at 
the anorectal ring and extends to the anal verge.7 The anorectal ring is situated about 5 cm 
from anal verge and forms as the anorectal angle.  It is about 3.5 – 5cm in length and forms 
the terminal part of the entire alimentary tract.8 The anal margin is defined as the area 5cm 
from the anal verge and is covered by epidermis.   
The epithelium lining the anal canal changes within the canal.  The dentate line is a 
landmark about 2 cm from the anal verge. The mucosa of the upper anal canal is lined by 
columnar epithelium. Below the dentate line, the anal canal is lined with squamous 
epithelium. The change is not abrupt.  For a distance of 0.6 to 1.2 mm above the dentate 
line, there is a gradual transition where columnar, transitional, or squamous epithelium may 
be found. This area has been referred to as the transitional or cloacogenic zone and is 
important when considering neoplasms that arise from this segment.7 The area between the 
dentate line and anal margin does not contain hair, sebaceous or sweat glands.  The 
epithelium above the dentate line is supplied by the autonomic nervous systems and the 




Figure 1.  Anatomy of the anal canal 9 
 
The anal canal descends postero-inferiorly between the anococcygeal ligament and the 
perineal body. It is surrounded by internal and external sphincters.  The internal anal 
sphincter is an involuntary sphincter surrounding the superior two thirds of the anal canal.  
The external anal sphincter is a large voluntary sphincter that forms a broad circular muscle 
around the inferior two thirds of the anal canal.10 
1.2 Incidence 
SCC of the anus represents approximately 1.5% of the newly diagnosed cancers of the 
gastrointestinal tract and 1 to 8% of all anorectal malignancies.11 In general, it is more com-
mon in women than men and usually occurs in the sixth or seventh decade of life.8 The 
incidence of SCC of the anus is increasing.  The incidence rate of invasive anal carcinoma in 
the United States increased by approximately 1.9-fold for men and 1.5-fold for women from 
1973–1979 to 1994–2000.12 The first published series in Africa, by Madden et al in 1981 
reported 55 cases over 20 years seen at Groote Schuur Hospital, a large urban teaching 
hospital.13   A recent review at the same intuition reported 31 patients over 4 years.  The 
median age was 56 years (range 18-87).  There were 15 females and 16 males.1 In this 
review anal cancer was calculated to represent 4% of all gastrointestinal tract cancers which 





1.3   Aetiology 
1.3.1 Physical Trauma or Inflammation 
Chronic inflammation was thought to be a risk factor for anal cancer after case reports of 
patients with inflammatory bowel disease.14,15  Frisch and colleagues reviewed the hospital 
records of 68549 patients in the Danish Cancer Registry and found that anal cancer had not 
developed in any of the 651 patients with Crohn’s disease or the 509 patients with ulcerative 
colitis.6,16  The presence of anogenital condylomata has been shown to increase the 
likelihood of anal cancer.  However there is no evidence of an association with 
haemorrhoids, fissures or fistulae.17 
1.3.2 Human Papillomavirus (HPV) 
HPV is a common viral sexually transmitted infection, with limited clinical stigmata; only 1% 
of patients will develop genital warts.18, 19 Frisch et al reported on 386 anal cancers and 
detected HPV in 90% of invasive cancers in women and in 63% of invasive cancers in 
men.20 In a similar study, Daling et al tested 262 anal cancers, and detected HPV DNA in 
87.9% of tumours, though the proportion of tumours positive for HPV was no different 




Chronic immunosuppression medication is a risk factor for several types of squamous-cell 
carcinomas, including those of the anal canal. In recipients of renal allografts, persistent 
human papilloma virus infection has been associated with a 100-fold increase in the risk of 
anogenital cancer.22, 23 Although an increased risk of anal cancer has not yet been 
demonstrated in patients who are receiving corticosteroids for autoimmune disease, these 




Several case-control studies have shown that a history of smoking increases the risk of anal 
cancer by a factor of two to five, independently of sexual practices.24, 25 This relation is 
supported by the finding that lung cancer is twice as frequent in patients with a history of 





1.3.5 Sexual Practices 
 
Using patients with colon cancer as controls, Daling et al reported the results of a 
population-based, case-control study of anal cancer conducted between 1978 and 1985.6,28 
Women with anal cancer were more likely to have a history of genital warts or infection with 
herpes virus or Chlamydia trachomatis compared to those with colon cancer.  Men with anal 
cancer were more likely to have engaged in homosexual activity, to have practiced receptive 
anal intercourse, and to have had a history of genital warts or gonorrhoea.  These 
observations were made before the human immunodeficiency virus (HIV) pandemic.  
Subsequent studies have confirmed the relation between anal cancer and receptive anal 
intercourse in men.29-31 Frisch et al compared 417 patients with anal cancer with 534 
patients with adenocarcinoma of the rectum and 554 normal control subjects.32 Multivariate 
analysis demonstrated that the relative risk of anal cancer in women was highest among 
those with 10 or more sexual partners compared to those with a history of anal warts, genital 
warts, gonorrhoea, or cervical neoplasia.  A history of receptive anal intercourse before the 
age of 30 years with multiple partners was also associated with an increased risk of anal 




The association between anal cancer and HIV infection is less clear, as HIV infection often 
co-exists with other risk factors, especially HPV infection.  Most population-based studies 
were done before widespread use of highly active antiretroviral therapy (HAART) and there- 
fore results might be different in current clinical settings.  Frisch et al studied the role of HIV 
in HPV related malignancies and they observed a higher risk for anal cancer in both men 
and women with acquired immunodeficiency syndrome (AIDS) (relative risk (RR), 6.8; 95% 
confidence interval (CI), 2.7–14.0 and RR, 37.9; 95% CI, 33.0–43.4, respectively).33 
Interestingly, they failed to show a higher risk among patients with CD4 counts less than 
200/mm3 compared to CD4 counts greater than 200/mm3. The authors concluded that while 
HPV-related malignancies are common, this may not be related to HIV-related 
immunosuppression but rather to unknown cofactors. Additionally, if HIV was directly 
associated with anal cancer, one would expect the incidence to decrease in the era after the 
introduction of HAART. This has been observed for other HIV-related malignancies, 
including non-Hodgkin's lymphoma and Kaposi's sarcoma, but not for anal cancer. A 
population-based study demonstrated that the incidence of anal cancer increased when 
comparing pre-HIV years (incidence, 0.6 per 100,000) with both HIV years (incidence, 0.8 




Table 1: Risk factors for Anal Cancer  6 
  Strong evidence 
   Human papillomavirus infection (anogenital warts) 
   History of receptive anal intercourse 
   History of sexually transmitted disease 
   History of cervical, vulvar, or vaginal cancer 
   Immunosuppression after solid-organ transplantation 
  Moderately strong evidence 
   Human immunodeficiency virus infection 
   Long-term use of corticosteroids 
   Cigarette smoking  
1.4 Screening 
Given the known high-risk groups for anal cancer, several studies have addressed screening 
in these populations.19 Similar to the cervical Papanicolaou (Pap) smears, anal swabs for 
cytology are a possible screening method for anal squamous intraepithelial lesion (SIL) and 
anal cancer. Sensitivity of anal cytology is in the range of 50%–80%, with sensitivity being 
higher in the HIV-positive population.8 Studies of the potential cost-effectiveness of 
screening have found that screening HIV-positive and HIV-negative homosexual and 
bisexual men every 2–3 years would be cost-effective and have life-expectancy benefit.35, 36 
Other groups in which there is a potential role for screening are women with a history of 
cervical dysplasia or cancer, and transplant recipients. 
1.5 Presentation 
The presentation of SCC of the anal canal is very similar to common benign anal conditions 
such as haemorrhoids and fissures, and is relatively non-specific.  Delays and misdiagnoses 
are common and the presence of benign conditions further obscures the diagnosis.8 Rectal 
bleeding is the most common initial symptom of anal cancer, occurring in about 45% of 
patients.  Anorectal pain or the sensation of a mass is present in 30%, while 20% of patients 
have no tumour-related symptoms.37, 38 Additional common symptoms include pruritus and 
anal discharge. Tenesmus and faecal incontinence can suggest tumour invasion into the 
anal sphincters.  Weight loss, change in stool calibre, constipation, inguinal 
lymphadenopathy and rectovaginal fistulae are indicators of advanced disease.8 
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1.6 Diagnosis and special investigations 
All suspicious lesions in the anal canal should be biopsied.  The examination should 
document the appearance, size, location, mobility and extent of the lesion.  If patient 
discomfort precludes adequate examination, an examination under anaesthesia (EUA) 
should be performed.8 As per local protocol, baseline investigations include full blood count 
(FBC), urea and electrolyte analysis (U&E), HIV, liver function tests (LFT) and a chest X-
ray.39 The size of the primary lesion is determined by direct examination.  Computed 
tomography (CT) scan of the abdomen and pelvis is used to evaluate the liver, the extent of 
local invasion and involvement of adjacent organs as well as pelvic and inguinal 
lymphadenopathy.  All clinically suspicious inguinal lymph nodes should be assessed by fine 
needle aspiration (FNA) or open biopsy.  Positron emission tomography-CT (PET-CT) scan 
does not replace a diagnostic CT and the routine use of a PET-CT scan for staging or 
treatment planning has not been validated.40   Bone scan, CT chest, magnetic resonance 
imaging (MRI) of the pelvis and abdomen can be added if there is a specific indication or 
diagnostic doubt.39 For women, a gynaecologic examination should be done, including 
screening for cervical cancer.  
1.7 Staging 
Unlike other gastrointestinal malignancies, the staging of anal carcinoma remains un-
changed following the revisions of the American Joint Committee on Cancer Staging (AJCC) 
version 7.0 system.40  (Table 2) 
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Table 2:  AJCC staging system for anal canal carcinoma 40 
 
Primary tumour (T-stage) 
 
Tx  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
Tis  Carcinoma in situ 
T1 Tumour 2 cm or less in greatest dimension 
T2  Tumour more than 2 cm but not more than 5 cm in greatest dimension 
T3 Tumour more than 5 cm in greatest dimension 
T4  Tumour of any size invades adjacent organ(s), e.g. vagina, urethra, bladder (Direct invasion of 
the rectal wall, perirectal skin, subcutaneous tissues, or sphincter muscle(s) is not classified as 
T4.) 
 
Regional lymph nodes (N-stage) 
 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1  Metastasis in perirectal lymph node(s) 
N2  Metastasis in unilateral internal iliac and/or inguinal lymph node(s) 
N3  Metastasis in perirectal and inguinal lymph nodes and/or bilateral internal iliac and/or inguinal 
lymph nodes 
 
Distant metastases (M-stage) 
 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 




Stage 0   Tis   N0   M0 
 
Stage I   T1  N0   M0 
 
Stage II   T2   N0   M0 
T3  N0   M0 
 
Stage IIIA  T1   N1   M0 
T2  N1   M0 
T3   N1  M0 
T4   N0   M0 
 
Stage IIIB  T4   N1   M0 
Any T   N2   M0 
Any T  N3   M0 
 








Before the introduction of CMT in 1974, APR was routinely performed for tumours arising in 
the anal canal.  This radical procedure required removal of the anorectum with creation of a 
permanent colostomy.  In early series, the overall probability of five year survival following 
APR for anal canal cancer was 40 to 70 %, with a perioperative mortality rate of 3%.38, 41-45 
APR fell out of favour as the initial therapy as increasing evidence demonstrated that SCC of 
the anal margin had a favourable prognosis and rarely required radical surgery.  Wide local 
excision (WLE) with primary closure could be performed for anal margin SCC.  Although 
local recurrence rates were as high as 50%, a second local excision or inguinal 
lymphadenectomy was able to salvage the majority of patients.  The five-year survival for 
patients with cancers less the 2 cm in greatest dimension was over 80%.41,42,46 Nigro et al 
published a landmark report in 1974 describing 3 patients treated with neo-adjuvant 
chemoradiotherapy. They noticed two patients had complete pathological response on 
surgical specimens and one patient had a complete clinical response but refused surgery.2 
Subsequent reports of patients by Nigro 47,48 showed an overall 5-year survival of 80% (34% 
of tumours > 4cm), with a 93% clinical tumour response and an 89% pathological response.  
Thereafter routine APR was abandoned, and surgery was used only for salvage if residual 
tumour was found on biopsy 6 to 8 weeks after initial therapy.  
1.8.2 Chemoradiotherapy 
The Nigro protocol consisted of  5 flurouracil (5-FU) (1000mg/m² per day by continuous in-
fusion days 1 through 4 and 29 through 32), mitomycin (10 to 15mg/m² on day 1 only), and 
intermediate dose radiotherapy (30 Gy).  The finding that the first three patients had 
complete pathologic or clinical responses led to the development of strategies that were 
directed at preservation of the anal sphincter.  In a follow up series, patients with anal canal 
cancer were initially treated with chemoradiotherapy (same regimen) and proceeded to an 
APR only if there was residual tumour on a post radiation biopsy. 49 The majority of patients 
treated with chemoradiotherapy were cured (five-year survival 67%) without an APR (five-
year colostomy-free survival 59%). 
These findings were subsequently confirmed by several other studies using a variety of 
regimens. (Table 3)  Taken together, the use of combined chemoradiotherapy resulted in 
local failure rates of 14 to 37 percent, five year overall survival rates of 72 to 89 percent, and 
five-year colostomy-free survival rates of 70 to 86 percent.49-55 As a result of this data, the 
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use of concurrent radiotherapy (RT) with infusional 5-FU and mitomycin has become 
established as the standard of care for patients with SCC of the anal canal. 
The necessity of including chemotherapy in the non-operative treatment regime for anal 
cancer has been addressed in at least two randomized trails. 
The Anal Cancer Trial Working Party of the United Kingdom Coordination committee on 
Cancer Research (UKCCCR) randomly assigned 585 patients with T1 to T4 SCC of the anal 
canal or margin to receive either RT alone (45 Grey (Gy) external beam in 20 or 25 fraction 
over four to five weeks plus a 15 Gy external beam or 25 Gy brachytherapy boost), or RT 
plus concurrent infusional 5-FU (1000mg/m² for four days or 750 mg/m² for five days during 
the first and final weeks of RT) and mitomycin (12 mg/m² on day 1 only).56 
Chemoradiotherapy was associated with significant reductions in local failure and mortality 
secondary to cancer.  However there was more acute morbidity, including six deaths, in the 
combined modality therapy group, but late morbidity was similar.  Overall survival was 
similar between the two groups, which was attributed to an early increase in non-anal cancer 
deaths in the first five years, which disappeared by year 10.57 Only 11 patients in the 
chemoradiotherapy group suffered a loco-regional relapse as a first event after 5 years. 
In a second trial, The European Organization for the Research and Treatment of Cancer 
(EORTC) randomly assigned 110 patients with locally advanced (T3-4 or N1-3) anal cancer 
to receive RT (45 Gy with a 15 or 30 Gy boost) with or without concurrent infusional 5-FU 
(750mg/m² per day on days 1 through 5 and 29 through 33) plus mitomycin (15 mg/m² day 1 
only).58 Chemoradiotherapy was associated with a significantly higher pathologic complete 
remission rate (80 versus 54 %), an 18% higher five-year loco-regional control rate, a 32% 
higher colostomy-free rate, and higher event-free and progression-free survival.  Overall 
survival was not significantly different and, in contrast to the UKCCCR trail, the incidence of 









Table 3 Multimodality Treatment of Anal Canal Cancers 9 
  
 
Complete   
 
Overall APR/  APR/colostomy  
 
    Radiation     
       dose 
tumour 
regression 
  3 -5 year    
   survival  
  colostomy                   
        rate 
 for 
complications 
Series (GY)  (%) (%)  (%)  (%) 
      Nigro et al 1983  
47 
 30 75 78 18 0 
Michaelson et al 1983  
58
 30 53 78 - - 
Cummings et al 1984  60 50 93 70 13 13 
Greenall et al 1985 
 44
 30-50 72 78 38 0 
Sischy 1985 
 61
 45 85 64 12 - 
Meeker et al 1986  62 30 88 87 15 0 
Nigro 1987  63 30 89 83 9 0 
Flam et al. 1987  64 41-45 87 90 3 0 
Papillon and Montbarbon 1987  65 42-62 81 80 10 3 
Sischy et al (RTOG 8314) 1989  53 41 90 73 6 - 
Nigro et al 1989  66 30 91 79 11 0 
Tveit et al 1989  67 50 87 58 29 12 
Lopez et al 1991  68 30-56 88 79 15 6 
Miller et al 1991 
 69
 30 88 87 12 - 
Rich et al 1993  70 56-60 89 94 22 0 
Allal et al 1993  54 48-68 66 75 19 6 
Tanum 1992  71 50 84 72 6 - 
Grabenbauer et al 1994  72 50 93 77 - - 
Beck and Karulf 1994  73 30-45 97 89 10 3 
Smith et al 1994 
 74
 30 98 91 21 0 
Basser et al 1994  75 30-60 77 81 - - 
Martenson et al (ECOG E7283) 1995  55 41 73 58 15 0 
Bartelink et al 1997 (EORTC) 
 58
 45-65 80 56 25 8 
Arnott et al (UKCCCR) 1996 
 56
 45 39 65 20 5 
Flam et al (ECOG/RTOG) 1996  76 45-50.4 82 76 9 1.5 
Martenson et al (ECOG E4292) 1996  77 59.4 68 - - - 
Gabriele et al 1997  78 50 100 78 4 4 








The need for mitomycin has been questioned since it does not sensitise tumour cells to the 
effects of RT, has only modest anti-tumour activity against SCCs and is associated with 
renal, pulmonary and bone marrow toxicity.79,80 The need for mitomycin in curative treatment 
of anal cancer was addressed in a joint trial from the Radiation Therapy Oncology Group 
(RTOG) and the Eastern Cooperative Oncology Group (ECOG) in which 310 patients with 
anal cancer of any tumour or nodal stage were randomly assigned to combined modality 
therapy with or without mitomycin.76 Patients who received mitomycin had significantly better 
four-year colostomy-free survival (71 versus 59%) and disease-free survival (73 versus 
51%), but pathologic complete response rates and overall survival were similar.  Grade 4 
toxicity (23 versus 7%) and fatal neutropenic sepsis (4 versus 1 patient) were significantly 
more common in the mitomycin group.  The authors concluded that, despite greater toxicity, 
the use of mitomycin in a definitive complete response regime for anal cancer was justified. 
Cisplatin is more active in the treatment of SCC of other organs than mitomycin.  Early 
uncontrolled studies suggested encouraging colostomy-free and overall survival rates with 
the substitution of cisplatin for mitomycin in the treatment of anal cancer.50-52,81 This has 
been addressed in two large controlled studies with conflicting results.82,83  The substitution 
of cisplatin for mitomycin in the treatment of anal cancer was not supported by the results of 
the US Intergroup trial (RTOG 98-11).82  On the other hand, the therapeutic equivalence of 
cisplatin and mitomycin when used in combination with infusional 5-FU concurrent with RT 
was suggested in the ACT II randomised trial of 940 non-HIV infected patients with anal 
SCC.83 Taken together, this data suggests that 5-FU plus mitomycin remains the standard of 
care, but 5-FU and cisplatin could also be considered a reasonable approach.  There 
appears to be no role for induction chemotherapy or a continuation of chemotherapy after 
chemoradiotherapy. 
Patients are typically treated with external beam RT using fields that initially encompass the 
pelvis from the S1-S2 level, inguinal lymph nodes (even if palpably negative), and anus.  
After a dose of 30 to 36 Gy is reached, the treatment fields are reduced to the low pelvis 
encompassing the anal tumour and the total dose to the primary tumour is 45 to 50 Gy in 
daily 2 Gy fractions. If there is palpable or radiographic evidence of inguinal node 





1.8.3 Persistent or Recurrent Disease 
The effects of chemoradiation on anal cancer persist for weeks after completion of 
treatment. Response is best assessed at least 6–8 weeks after completion. There is 
currently no consensus as to whether response should be assessed by physical examination 
alone or in combination with a biopsy. It is also not clear whether biopsy should play a role in 
the management of those individuals with a complete clinical response.19 
There is little data available about predictors of local failure.  In a retrospective study 
Renehan and colleagues evaluated the outcomes of 254 patients with anal cancer treated 
with either radiotherapy alone (n = 127) or combined chemoradiation (n = 127) between 
1988 and 2000 at a hospital in the United Kingdom, and found that local failure occurred in 
99 (39%) patients and the median time to failure was 20.4 months. 85 Five-year local failure 
rates were significantly different between those patients receiving radiation alone (52.5%) 
and those patients receiving combined chemoradiation (35.3%). For patients receiving 
radiation alone, age, total radiation dose <50 Gy and higher T stage predicted local failure. 
However, for patients receiving combined chemoradiation, no single factor was predictive of 
local failure. 
The preferred treatment for persistent disease following combined modality therapy is APR. 
This surgery is radical and associated complications appear to be greater in patients under-
going APR after combined modality therapy.86  Nilsson and colleagues retrospectively 
evaluated the outcomes of 35 Swedish patients (21 with persistent disease and 14 with 
recurrent disease) undergoing salvage APR following loco-regional failure after combined 
modality therapy for anal squamous carcinoma.87  Thirteen patients developed perineal 
wound infection necessitating re-operation, and 23 patients had delayed wound healing 
(defined as healing time >3 months). In addition 15 patients, 12 of whom had undergone 
salvage APR for persistent disease, experienced secondary failure. The median survival 
duration after secondary failure was 19 (range, 1–78) months. In the UKCCCR trial, there 
were 29 patients who underwent salvage APR; 40% eventually relapsed.56 
Salvage chemoradiation therapy for persistent disease has also been evaluated.84 In the 
Intergroup study evaluating the role of mitomycin, those patients with persistent disease 
received salvage 5-FU, cisplatin, and 9 Gy EBRT. Of 29 patients treated in this manner, 10 





1.8.4 Inguinal nodal disease 
Metastatic spread to the inguinal nodes can occur in 15–60% of anal cancer patients at 
some time during the course of the disease. The risk is associated with the size and location 
of the primary lesion. Suspicious inguinal lymph nodes found at initial presentation should be 
assessed with FNA or open biopsy. Pelvic irradiation fields for SCC of the anus include the 
inguinal nodal basins whether metastatic disease is evident or not. For synchronous nodal 
disease, radiation therapy to the nodal basins or CMT with inclusion of the nodal basins in 
the treatment field provides good results with initial disease control rates of 65% and 90%, 
respectively.8 For persistent inguinal disease, therapeutic lymph node dissection can be 
offered. Similarly for patients with recurrent or metachronous inguinal disease, lymph node 
dissection can provide good long-term results, with 5-year survivals over 50% reported.44  
Additional chemotherapy and radiation therapy can be offered as an alternative if the nodal 
basin has not reached treatment tolerance. Inguinal lymph node dissections in a radiated 
field are associated with significant wound morbidity due to seroma and infection. In highly 
irradiated fields, closure with rotational musculocutaneous flaps may decrease morbidity. 
1.8.5 Treatment of distant metastatic disease 
Approximately 10% of patients with SCC of the anus will have distant metastatic disease at 
presentation, the usual sites being liver and lung. For patients with inguinal 
lymphadenopathy or a tumour greater than 5 cm, distant metastases may develop in up to 
25% of cases at some point in the course of the disease. The development of distant 
metastatic disease portends a uniformly poor prognosis. Currently available treatment in this 
setting is palliative. Salvage chemotherapy using cisplatin-based regimens, often in 
combination with 5-FU, offer some efficacy. However, complete responses are rare, and 
duration of response is often short. Radiation therapy for symptomatic metastases can be 










1.9 Defunctioning stomas 
Some patients will require a defunctioning colostomy prior to CMT to allow for safe delivery 
of treatment with the lowest risk of treatment interruption.3 The indications for pre-treatment 
colostomies are large bowel obstruction, faecal incontinence usually due to destruction of 
the anal sphincter by tumour, presence or risk of fistula formation, which usually occurs 
when macroscopic tumour invades the vagina, and pain. (Table 4) 
 
Table 4: Indications for pre-treatment defunctioning stomas 
    Cooper et al 2010 3  Sunesen et al 2011 4  
    35 of 344 patients  20 of 235 patients
 
Vaginal fistula    15    6 
Obstruction    1    4 
Incontinence    10    5 
Abscess     4    4 
Pain     5 
Unknown        1 
 
      
Diverting stomas are offered with temporary intent, with reversal planned after completion of 
organ preserving treatment with CMT.  Four different authors noticed in their respective 
series that this was not necessarily the case. 
De Bree and colleagues from the Netherlands reported on 83 patients over a 20 year period. 
Seven (8%) patients needed defunctioning colostomies prior to CMT.  Four (57%) of the 7 
patients retained their initially temporary colostomy because of either progressive disease 
(n=1), recurrent disease (n=2) or a persistent anal ulcer (n=1). One patient with a 
prophylactic colostomy underwent APR for residual disease. The remaining 2 patients were 
relieved from their colostomy 3 and 4 months after the initiation of RT, but 1 of them later 
underwent a diverting colostomy for a late radiation ulcer. 88 
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Cooper et al evaluated 344 cases of anal cancer between 1997 and 2007. Thirty five 
patients treated with radical intent needed a defunctioning stoma prior to CMT.  Seven (20%) 
patients had the stoma reversed subsequently. The reasons for non-reversal were 
progressive disease (n = 9), persistent fistula (n = 3), predicted poor function (n = 4), cavity 
formation (n = 1), fibrosis (n = 3), death from another cause (n = 2), patient choice (n = 3) 
and salvage surgery (n = 2).3 
Sunesen et al from Denmark reviewed 235 patients diagnosed with anal canal SCC between 
1995 and 2003, of which 20 needed pretreatment stomas.  One year after the completion of 
radiotherapy the only patient with reversal of a pre-treatment colostomy had a second 
colostomy as a result of faecal incontinence.4 
A cohort from Groote Schuur Hospital of 31 patients between 2000 and 2004 was published 
by Robertson et al.  Seven patients required stomas prior to chemoradiation.  Only one 
patient had an attempt at closure but subsequently developed faecal incontinence and 
required re-placement of the colostomy.1 
From above it can be postulated that if a patient requires a defunctioning colostomy for anal 
cancer prior to CMT for any indication the patient is likely to have a permanent stoma.   The 
rationale of combined modality treatment as originally described by Nigro et al is organ 
preservation and in other words, avoidance of permanent stoma.  It is thus not clear whether 
this protocol is most beneficial for this small specific subgroup of patients.  It may be that this 
subgroup of patients actually represents advance disease and that the need for a 
defunctioning colostomy implies a poor prognostic outcome.  Nevertheless, the impression 
remains that colostomies created before initiation of radiotherapy or chemoradiotherapy for 
anal cancer are not reversed.  Patents should be informed that a pre-treatment colostomy is 
probably permanent.1, 3,4,88 With this knowledge, the surgeon should plan the operation to 
achieve a stoma that will best serve the patient long term.  A transverse colostomy, with its 
tendency to prolapse, should be avoided and some authors prefer an ileostomy for which 
spill-over in the distal limb is uncommon. (3)  Ileostomy is not universally accepted and most 
would still do a loop sigmoid stoma.  An end stoma with closure of the distal limb could also 
be considered as the danger of a closed loop obstruction is very rare.   The possibility of 
more radical surgery in the form of an APR might be suggested.  This would mean that 




1.10 Complications of chemoradiation  
CMT has both acute and chronic side effects.  Acute effects include diarrhoea, mucositis, 
skin erythema and desquamation, and myelosuppression (thrombocytopenia and 
neutropenia).  Late complications, some of which necessitate surgery with or without 
colostomy, include anal ulcers, strictures, fistulae and necrosis.19 Reported late event rates 
following chemoradiation therapy for anal cancer are in the range of 3%-16%.86  The 
inclusion of inguinal radiation fields is associated with epidermolysis, leg oedema and 
vascular damage.89 
In a recent Groote Schuur review, 7% of patients did not complete their treatment due to 
toxicity, and 38% required treatment interruptions. A further 7% needed permanent stomas 
for late toxicity.1 
Based on the 2 phase III trials, RTOG 98-11 and ACCORD 03, and earlier studies with 
planned treatment delays, it is clear that any treatment delays in the initiation of -, or during 
chemoradiation therapy are deleterious for patient outcomes. Should treatment related 
toxicities be a concern, rather than withholding all chemoradiation therapy, chemotherapy 
may be deferred temporarily if needed, but radiation therapy should not be withheld for 
prolonged periods unless medically necessary.90-93 
The use of mitomycin has been associated with a higher risk of acute hematological toxicity, 
typically manifesting as neutropenia.  In the RTOG trial, there were four deaths in the 
mitomycin arm, all due to neutropenic sepsis, compared with one death in the 5-FU alone 
arm.64 
Gastrointestinal side-effects are frequently observed during radiotherapy of malignancies in 
the abdomen and pelvis.  Radiation-induced diarrhoea requires regular symptomatic 
medications.94  Sacral insufficiency fractures after pelvic radiation occur more commonly than 
previously described.  Independent risk factors associated with fracture were osteoporosis, 
female gender and age greater than 60 years.95 Fertility is often impaired after chemotherapy 
and radiotherapy.  Cytotoxic therapy influences spermatogenesis at least temporarily and in 
some cases permanently.96 
Secondary cancers are a known complication of radiotherapy, but there is no clear evidence 
associated with the Nigro protocol.  In a large cohort of 2658 patients of prostate cancer 
patients the incidence of a secondary malignancy after radiotherapy was not significantly 




1.11 Fate of a long term defunctioning stoma 
Diversion proctocolitis is an iatrogenic disorder caused by surgical diversion of the faecal 
stream away from the colorectal mucosa.  A chronic lymphoplasmocytic inflammatory 
infiltrate and the hallmark feature, lymphoid follicular hyperplasia, characterize the 
histopathological changes.  Diversion colitis can be asymptomatic or present with blood and 
mucous discharge and abdominal pain.98 
1.12 Complications of APR 
Complications from APR are similar to those of any major abdominal procedure, including 
sepsis, myocardial infarction, pulmonary embolus, and wound problems. There are some 
specific problems related to APR, although usually described with the operation when it is 
done for rectal cancer.   These include impaired sexual function.  There is at least a 50% 
incidence of significant impotence in men after resection of the rectum for cancer.99 
Perineal wound complications are common following APR.  In the largest review of perineal 
wound complications by Christian et al, the overall rate of perineal complications following 
APR was 35 percent, with 14 percent being major wound complications and 24 percent 
minor wound complications. Pre-operative radiation appeared to increase the risk of major 
wound complication for patients with anal cancer.100 
A specific problem that can occur intra-operatively during the performance of the rectal 
dissection is massive venous bleeding from the presacral space. Urethral injury can also 
occur, but again uncommon when the operation is being done for anal pathology.99 
Complications which occur after formation of a stoma include ischemia, retraction, hernia, 
stenosis, prolapse and fistula.  
The operative mortality after an APR should be less than 2%. As with all forms of major 
abdominal surgery, improved anaesthesia and the use of invasive perioperative monitoring 











The aim of this study was to evaluate the stoma closure rate of patients needing 
defunctioning colostomies prior to CMT for anal SCC at GSH. The key objective was to 
assess if abdomino-perineal resection (APR) should be offered as primary treatment 





All patients who presented to the Combined Colorectal Clinic at Groote Schuur Hospital with 
a histologically proven diagnosis of anal squamous cell carcinoma over a 17 year period 
from 01 April 1995 to 30 June 2012, were included in this study. Prior to April 1995 patients 
were treated using a different protocol and were excluded.   The charts of the patients were 
retrospectively reviewed. 
The Combined Colorectal Clinic is a weekly multidisciplinary team meeting and all 
management decisions regarding colorectal, including anal, cancers are undertaken there.  
The team consists of specialist colorectal surgeons, radiation oncologists, diagnostic 
radiologists, social workers and stoma therapists.  The Combined Colorectal Clinic’s weekly 
patient lists and appointment books for the given period were the basis for identifying 
patients with SCC of the anus.  Names were extracted from an electronic database and 
manually checked in appointment books.  
Approvals from the Department of Surgery Research Committee and the Faculty of Health 
Sciences Human Research Ethics Committee (HREC 429/2012) were obtained prior to 
accessing data. (Appendix p. 55) 
The patient charts were obtained from medical records and a numeric code assigned in 
order to maintain confidentiality.  Both GSH folders for the surgical notes and the separate 
oncology folders were studied.  The National Health Laboratory Services’ DISALAB online 
results facility was used to verify blood and histology results. 
Demographic data including age at presentation, race and gender were recorded to 
characterize the cohort.  Risk factors for anal SCC namely; smoking, HIV status with CD4 
count and HPV status were documented.  Unfortunately testing for HPV was not routinely 
done in all patients.  Although sexual orientation and sexual practice are important 
considerations in anal cancer, this information was not part of the original data collection, 
and was therefore not included in the current study.  
Tumour characteristics were documented and subdivided into well, mild or poorly 
differentiated squamous carcinoma.    Staging was documented in the standard TNM format 
of the American Joint Committee on Cancer Staging system.  The maximum diameter of the 
tumour was also documented.  Both anal canal and anal margin cancers were included in 
the data collection.   
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The treatment plan was documented as palliative or radical (curative) intent.  Data collection 
included patients treated with palliative intent.  Patients with anal margin carcinoma had a 
wide local excision if it was deemed as resectable with preservation of the sphincter.  The 
histology, specifically the resection margin was documented.  
For patients treated with chemoradiation, the radiation dose was either 42.00 Gy in 20 
fractions (1995 to May 2003) or 44.20 Gy in 20 fractions (after June 2003), four fractions 
weekly using 60-Cobalt. Anterior and posterior fields to the pelvis were based on bony 
landmarks as well as tumour extent. The superior border of the radiation field was placed at 
the lower border of the sacroiliac joint or the upper border of the acetabulum. The inferior 
border was placed 2 cm below the anal verge or 2 cm below visible tumour if the tumour 
protruded from the anal canal. For patients with no inguinal node involvement the lateral 
border was 1 cm lateral to the widest brim of the pelvic sidewalls. In patients with involved 
inguinal nodes the lateral border was placed 2 cm lateral to the palpable nodes. Patients 
without stomas were treated prone.  The chemotherapy regimen was mitomycin C 12 mg/m² 
on day 1 and 5FU 1 000 mg/m² as a continuous infusion on days 1 - 4, i.e. with the first four 
fractions, and 5FU 1 000 mg/m² with the last four fractions of irradiation. 1, 38 
All patients were reviewed 6 weeks after completing treatment. If the size of the primary 
tumour had decreased by more than 50% a further dose of 15.00 Gy in 6 fractions was given 
to the perineum. Patients with less than 50% response were evaluated for surgery. The 
response to treatment for patients receiving chemoradiation was assessed clinically at the 
completion of treatment.1, 38 Side effects of radiotherapy and whether a treatment break was 
needed for severe skin toxicity were noted.  The histology of those requiring salvage APR 
was reviewed to assess residual disease and resection margins. 
In the patients who required a stoma prior to chemoradiotherapy, the indication for the 
stoma, the type of stoma, the closure rate and reason for non-closure were recorded.  To 
evaluate the resectability of these patients pre-radiotherapy the operation notes of the 
examination under anaesthesia and the comments of the operating surgeon were noted.  









Data and variables were collected and analysed on a Microsoft Excel 2010 spread sheet.  
The data sheet was password protected to ensure confidentiality.  All captured data was 
kept anonymous.   
This study contains mostly descriptive statistics therefore no bio statistical package was 





























4.1 Patient demographics  
One hundred and forty one patients treated for cancer of the anus during the 17-year period 
from 01 April 1995 to 30 June 2012 were identified.  Sixteen patients were excluded.  The 
reasons for exclusion included either a different histological diagnosis, incomplete 
histological diagnoses (n=5), or medical records unobtainable (n=11).  One hundred twenty 
five patients were analysed.  The demographic characteristics are summarized in tables 5 
and 6.  There were 58 (46.4%) males and 67 (53.6%) females with a mean age of 56 (±13) 
years.  
The HIV status was reported in 88 patients, and only 10 (11.4%) were positive for HIV.  The 
majority of patients were smokers (n=78), while 21 were non-smokers, and the smoking 
status was not recorded in 26 patients.  
Table 5:  Demographics and risk factors of 125 patients with anal squamous cell carcinoma 
 
 
Characteristic       n  (%) 
 
Sex 
 Male       58  (46) 
 Female       67  (54) 
 
Age (years) 




 Tested       88  (70) 
 Negative      78  (89) 
 Positive       10  (11) 
 Unknown      37  (30) 
 
Smoking 
 Yes       78  (62) 
 No       21  (17) 







                                
Figure 2:  Age distribution 
 
4.2 Tumour characteristics 
The mean tumour size was 5,5cm (range 0 -12 cm).  Seventy two patients (58%) had a 
tumour greater than 5cm.  The HPV status was not part of routine testing. However 7 
patients were reported to have HPV on their histology, and four of these were HIV positive. 
Fourteen tumours were well differentiated squamous cell carcinoma; 42 were moderately 
differentiated and 22 poorly differentiated.  In 47 patients the degree of differentiation as not 
recorded. (Figure 3) 
 
 












Well Moderate Poor Unknown
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4.3 Treatment 
One hundred and seven of the 125 patients received treatment with curative intent. 
(Figure 4)  Eighteen patients were offered palliation, either with a palliative stoma or 
radiotherapy.  The main indications for palliation were advanced or systemic disease and 
patients medically unfit for CMT.  (Table 6) 
Figure 4:  Treatment intent 
Table 6:  Indication for palliative stomas (n=9) 
Obstruction 1 
Incontinence 1 
Sepsis  3 






The patients with anal margin cancer were evaluated if the lesion could be treated with wide 
local excision (WLE) without compromising the anal sphincters.  Eleven such patients were 
treated as anal margin cancer with a WLE.  Three of these needed a second WLE after 
surgical margins were noted to be involved after the first surgery.  None of these patients 
required a stoma.  Six patients were treated with an APR without CMT with good outcomes. 
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Table 7:  Indications and outcome of primary APR in anal SCC 
 
 Indication     Histological Margin
 
1  Evaluated as rectal pre-op   Involved 
2  Too frail for CMT    Clear 
3  Destruction of sphincters   Clear  
4  Previous radiotherapy    Clear 
5  Previous radiotherapy   Clear 




Ninety patients were treated with CMT based on the Nigro protocol.  The most common 
complication was skin toxicity in 37 patients, in which 14 needed interruption of their 
treatment.  Twenty-four patients received a pelvic boost dose after evaluation of response on 












Salvage APR was offered to 12 patients.  The indication and outcomes are summarized in 
table 8 and figure 7. 
Table 8:  Indications for Salvage APR after CMT 
Reason Number of patients (n=12)
Persistent disease 8 
Recurrent disease 3 
Non-functioning anus 1 
Figure 7:  Surgical outcomes of Salvage APR for Anal SCC 
Salvage APR 
n = 12 
Involved margin 
n = 3 
Clear margin 
n = 9 
Recurrence 
n = 4 
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Thirty patients required defunctioning colostomies prior to CMT with the most common 
indications being obstruction and incontinence. (Table 9)  Only 4 (13%) of these stomas 
were eventually reversed.  One patient had the stoma restored for incontinence post 
reversal. Three patients from this subgroup needed a salvage APR. (Figure 8) 
 
Table 9:  Indications for pre-treatment defunctioning stoma 
 
 Reason    Number of patients (n=30)
 
 Obstruction     14 
 Incontinence       8 
 Sepsis        1 
 Fistula        3 








































































The reason for non-reversal in 58% of these patients was disease progression.  Three were 
lost to follow up and it is presumed that they still had their stomas. (Table 10)  Therefore, of 
the cohort of 30 patients requiring pre-treatment stomas, only one was successfully 
reversed.   
 
Table 10:  Reasons for non-reversal of stomas 
 
 Reason    Number of patients (n=26)
 
 Disease Progression             15 
 Lost to follow up    3 
 Anal stenosis      3 
 Incontinence     1 
 Unknown     3 




Table 11:  Pre-treatment evaluation of stoma subgroup  
 
 Not resectable (clinical or radiological)   13 
 Patient not fit for major surgery      2 
 Inadequate data retrospectively      9 









Organ preservation is an important endpoint and the rationale behind CMT for anal SCC.  In 
our series 38% of the patients, including anal margin SCC, needed a permanent stoma.     
(Figure 9) 
 
Figure 9:  Permanent stoma in Anal SCC 
Permanent Stoma 
n = 48 
Primary APR 
n = 6 
Palliative stoma 
n = 9 
Salvage APR 






CMT is currently the standard of care for patients with anal canal SCC with favourable 
outcomes reported.  The good of CMT is cure of the cancer, with natural orifice preservation 
and avoidance of a permanent stoma.  This is achievable in the majority of patients with anal 
canal SCC who are treated with curative intent. In our study 39 (36%) of the 107 patients 
treated with curative intent had a permanent stoma at the end of their treatment.  Six 
patients (6%) had primary APR’s, nine (8%) had salvage APR’s and 24 (22%) patients who 
required pre-treatment defunctioning stoma, the stoma was never reversed.  This number is 
even more significant as this group included patients with anal margin SCC. 
In this series 30 (32%) patients with anal canal SCC treated with curative intent needed a 
temporary defunctioning colostomy to prevent treatment interruption of the CMT.  This is 
significantly higher than reported in other series (8 to10%) incidence of a defunctioning 
colostomy).3, 4, 88 In the literature between 0% and 20% of the pre-CMT treatment stomas 
were eventually reversed.  The conclusion of both Cooper et al and Sunesen et al was that 
pre-treatment stomas must be made with permanent intent.3, 4 They suggested that these 
patients should be consented and informed that the stoma is likely to be permanent.   This is 
not currently standard practice at GSH and our patients are treated with a laparoscopic 
assisted loop sigmoid colostomy with temporary intent. 
The most common reason for non-reversal in our series was disease progression in 58% of 
patients.  This figure correlates with that reported in the literature. Obstruction was the lea-
ding indication for defunctioning colostomy, which would suggest a more advanced T stage.   
Before the introduction of CMT, APR was the preferred treatment for anal cancer.  Madden 
et al reported a case series including 55 patients from our institution during the APR era and 
they suggested that even large carcinomas of the anal margin could be resected with a fair 
prognosis.  However the early intra-pelvic spread of carcinoma of the anal canal prevented 
APR from achieving a high cure rate.13 In the current series, five of the six patients who 
received an APR as primary treatment for anal SCC achieved clear surgical margins without 
significant perioperative morbidity.  
Lefevre et al reported on 95 patients who had an APR for anal SCC, including eight patients 
who had APR as primary modality due to a contra-indication to radiotherapy.  Five of the 
eight needed a vertical rectus abdominis myocutaneus flap.101 
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CMT for anal SCC is not universally well tolerated.  Radiotherapy caused skin toxicity in 41% 
of our patients, and 15% of the patients required treatment interruption because of this.  
Added to this is the systemic side effect profile of chemotherapy, with related mortality.  GSH 
services a large geographical area.  Patients are often from poor socioeconomic 
backgrounds without transport who have to travel long distances to the city to receive regular 
CMT.  This could be avoided with a single admission for surgery.  
If a defunctioning stoma is required for SCC of the anal canal, the use of an APR should be 
considered as an alternative approach.  As a result patients would avoid the side effects of 
CMT.  In the long term both groups of patients would have a permanent colostomy.  The 
majority of these patients would not be amenable to primary surgery or will require very 
radical surgery.  The alternative of neo-adjuvant radiotherapy would be counterproductive, 
as a diverting stoma with CMT would have the same functional outcome. In 6 patients who 
received a pre-treatment stoma the primary was deemed resectable before the initiation of 
the CMT.  This subgroup should be considered for an APR.  
The limitations of this study include its retrospective nature, relative small sample size and 
the short follow-up.  Unfortunately, when one studies a small subgroup within a rare disease 
it is difficult to obtain a large cohort of patients.  As APR is not the current preferred 
treatment for anal SCC, not all patients were evaluated or adequately documented if they 
were deemed resectable.  The presence of potential pathological nodes is one variable that 
would potentially change the outcome and the absence of this from the data is a limitation.  
Nine of the thirty patients needing defunctioning colostomies had inadequate information to 

















This study supports the observations of other authors, that a defunctioning stoma prior to 
CMT has a very high likelihood of being permanent.  Patients should be informed and 
consented in this regard.  Primary APR for anal squamous cell carcinoma had good results 
in previous older studies, and this was confirmed in this study for the patients treated with 
this modality. For these reasons, APR should be considered as primary treatment in a 
subgroup of patients requiring de-functioning stoma, as long as the disease is resectable.  
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Chapter 8 
List of abbreviations 
AIDS - Acquired immunodeficiency syndrome
AJCC - American Joint Committee on Cancer Staging
APR - Abdomino-perineal resection
CMT - Combined modality treatment
CT - Computer tomography
DNA - Deoxyribonucleic acid
EUA - Examination under anaesthesia
FBC - Full blood count
FNA - Fine needle aspirate
GSH - Groote Schuur Hospital
HAART - Highly active antiretroviral therapy
HIV - Human immunodeficiency virus
HPV - Human papillomavirus
LFT - Liver function tests
MRI - Magnetic resonance imaging
PET - Positron emission tomography
RT - Radiotherapy
SCC - Squamous cell carcinoma
SIL - Squamous intraepithelial lesion
TNM - Tumour, Lymph nodes, Metastasis
U&E - Urea & Electrolytes
WLE - Wide local excision
5-FU - Fluorouracil
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